Biotech Values

[kaivamei]

The extracts from the complaint support dewophile's theory that this is a reply to Teva's posturing (after all, it includes Teva mgmt's statements as exhibits). It reveals MNTA's argument that Teva simply could not meet the FDA criteria without infringing its patents. This is great stuff!

On another issue, the complaint does note that amendments to Teva's ANDA have been filed ("Teva filed an ANDA and amendments thereto with the FDA").

Thanks, stockbettor, for posting those extracts. Very interesting!